Canaccord Genuity Reiterates Buy Rating, $18 PT on Derma Sciences

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating and $18.00 price target on Derma Sciences (NASDAQ: DSCI).Canaccord noted, “We maintain our BUY rating following mixed Q2/12 results, with Y/Y revenue growth again driven by advanced wound care products while core products were soft due to weakness in the Canadian market. Management continues to execute on its AWC strategy, acquiring the rights to the Nimbus technology in the Q2/12. DSC127 is still on track for enrollment by YE/12.”Derma Sciences closed on Tuesday at $9.42.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!